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A B S T R A C T
Equine coronavirus (ECoV) is considered an enteric pathogen of foals and has only recently been asso-
ciated with infections in adult horses. Seroprevalence data is needed to better understand the epidemiology
of ECoV in adult horses, evaluate diagnostic modalities and develop preventive measures. The objective
of this study was to investigate the seroprevalence and selective risk factors for ECoV in 5247 healthy
adult horses in the USA, using a recently established and validated IgG enzyme-linked immunosorbent
assay. Prevalence factors analysed in this study included geographic region, age, breed, sex and use.
A total of 504/5247 horses (9.6%) horses tested seropositive. Geographic region (Mid-West; P = 0.008),
breed (Draft horses; P = 0.003) and specific uses of horses (ranch/farm, P = 0.034; breeding use, P = 0.016)
were all statistically significant risk factors for seropositivity.
© 2017 Published by Elsevier Ltd.
Introduction
Coronaviruses are part of the coronaviridae family, which are
positive-strand RNA viruses. The coronaviridae subfamily is grouped
into four genera, based on genetic differences and serological cross-
reactivity (Woo et al., 2009, 2012). Equine coronavirus (ECoV) is a
β-coronavirus, as are human coronavirus OC43 and HKU1, murine
hepatitis virus, bovine coronavirus (BCoV), porcine haemagglutinating
encephalomyelitis virus, canine respiratory coronavirus and rat
coronavirus (Zhang et al., 2007). ECoV is considered an enteric patho-
gen of foals (Guy et al., 2000) and has only recently been associated
with infections in adult horses in Japan, the USA and Europe (Oue
et al., 2011, 2013; Pusterla et al., 2013; Miszczak et al., 2014). Re-
portedmorbidity rates during outbreaks range from 20–83% (Pusterla
et al., 2013; Fielding et al., 2015; Giannitti et al., 2015).
Despite the sporadic occurrence of ECoV outbreaks in adult
horses, the overall seroprevalence of this virus in horse popula-
tions remains largely unknown. Seroprevalence data is needed to
better understand the epidemiology of ECoV, evaluate diagnostic
modalities and develop preventive measures. Therefore, the objec-
tive of this study was to investigate the seroprevalence and selective
risk factors to ECoV in 5247 healthy adult horses originating from
18 US states using a recently established and validated ELISA
(Kooijman et al., 2016).
Materials and methods
Study population
The study population consisted of 5247 healthy horses from 18 states (CA, CO,
FL, KY, MD, MN, MS, MO, NY, NC, OH, PA, TN, TX, VA, WA, WI, WY) representing the
four regions of the USA (North-East, South, Mid-West, West). States sampled from
the four regions were as follows: North-East (NY, MD, PA); South (FL, MS, KY, TN,
NC, VA, TX); Mid-West (MO, OH, WI, MN); West (WA, CA, CO, WY). Banked sera col-
lected by Zoetis USA for the purposes of another study were used. Blood samples
were collected by convenience sampling from healthy horses by equine veterinar-
ians from participating veterinary clinics across the USA during the autumn of 2013.
Clinics enrolled voluntarily and each clinic sampled approximately 110 horses; no
more than 10 horses sampled from each clinic resided on the same farm. Jugular
venipuncture was used to collect 10 mL of whole blood from each horse. Addition-
ally, age, breed, primary use, and sex data were collected for each horse by
questionnaire. Blood samples were centrifuged, serum was separated, shipped on
ice, processed and stored at −20 °C.
Serological analysis
All sera were tested for IgG to ECoV using an ELISA based on a recombinant protein
containing two immunodominant areas of the spike protein of ECoV, including the
area with the highest predicted antigenic sequence (Kooijman et al., 2016). Briefly,
microtiter plates were coated with 0.0156 μg recombinant protein per well and sera
were tested at a dilution of 1 μL serum in 100 μL of buffer. Each plate contained known
negative and positive controls. Negative controls consisted of sera collected from
healthy adult horses from the university herd with no history of systemic disease
and qPCR-negative feces for ECoV. Positive controls consisted of sera collected from
horses 30 days after they developed clinical signs compatible with ECoV infection
and tested qPCR-positive for ECoV in the faeces. A secondary horseradish-peroxidase
labelled IgG was used to bind with ECoV-specific antibodies from the serum samples.
An enzyme substrate (Bethyl ELISA starter accessory kit II) was used to detect the
secondary antibody. The optical density (OD) of each well was measured and
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corrected by subtracting the average of the OD values of the negative control samples.
Sera were considered positive if the corrected value was above the average plus three
times the standard deviation of the OD of the negative control samples (Kooijman
et al., 2016).
Statistical methods
Risk factors analysed in this study included geographic regions (North-East, South,
Mid-West, West), age, breed (Quarter horse, Warmblood, Thoroughbred, Paint horse,
Arabian, Draft horse, Pony/miniature, other), sex (female, gelding, male) and use (com-
petition, ranch/farm, breeding, other). Age was analysed in 5-year increments as a
categorical variable.
Univariate logistic regression (controlling for the random effect of farm of origin)
of each prevalence factor was performed to determine the odds ratios associated
with region, age, breed, sex and use. Further, a mixed effects logistic regressionmodel
was developed to include significant risk factors and the random effects parameter
of horses originating from the same farm. All statistical evaluations analyses were
performed in Stata 12 (Stata statistical software, Version 12) and statistical signif-
icance was set at P < 0.05.
Results
The total number of ECoV positive horses was 504/5247 (9.6%).
The seroprevalence per state ranged from 4.0–19.7% (Table 1). Fig. 1
shows the number of horses sampled in each region and the rates
of seropositive samples (%). Horses aged >20 years (13.0%), Draft
horses (17.6%) and ranch/farm horses (12.0%) had the highest
seroprevalence (Table 2). The median age of the study population
was 11 years (range, 2–40 years).
Statistically significant risk factors in the mixed effects univari-
ate analysis included region (Mid-West), age (>20 years old), breed
(Draft horse, Thoroughbred) and use (ranch/farm). There was no sig-
nificant difference in risk for ECoV seropositivity between male and
female horses.
In the mixed effects multivariate model, horses from the Mid-
West displayed the highest odds ratio of seropositivity in the region
category when compared to the reference region (Table 3). Draft
horse showed the highest odds ratio of seroprevalence in the breed
category, while Thoroughbreds had the lowest odds ratio of
seroprevalence. Ranch/farm and breeding horses displayed the
highest odds ratio of seroprevalence in the use category. There was
no significant difference between male and female horses and
between the reference age group and the other age groups.
The total number of ECoV negative horses was 4743/5247 horses
(90.4%). Table 2 shows the number (%) of seropositive and sero-
negative horses sampled for each of the risk factor categories.
In the univariate model, horses aged 1–5 years old had 91.7% se-
ronegativity, Thoroughbreds had the highest % seronegativity (95.1%)
and competition horses had the highest % seronegativity (92.4%).
In the mixed effects multivariate model, horses from the Mid-
West were least likely to be seronegative, Thoroughbreds were most
likely to be seronegative and Draft horses were least likely to be se-
ronegative (Table 3). There was no significant difference in odds for
seronegative status by age group, sex and use.
Table 1
Frequency of equine coronavirus (ECoV) seropositivity per state as defined by ELISA
in 5247 equine sera collected from 18 different states.
State (n) ECoV positive
samples (%)
Maryland (100) 4 (4)
Colorado (321) 15 (5)
Virginia (262) 13 (5)
Pennsylvania (220) 13 (6)
Kentucky (328) 22 (7)
Washington (320) 21 (7)
Florida (327) 25 (8)
New York (330) 25 (8)
Tennessee (220) 18 (8)
Texas (330) 26 (8)
California (328) 30 (9)
Missouri (330) 34 (10)
North Carolina (330) 32 (10)
Ohio (320) 34 (11)
Wyoming (419) 53 (13)
Mississippi (110) 17 (15)
Wisconsin (322) 57 (18)
Minnesota (330) 65 (20)
Fig. 1. Frequency of equine coronavirus (ECoV) seropositivity by ELISA per region in 5247 equine sera collected across the USA.
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Discussion
To the authors’ knowledge, this is the first seroprevalence study
of ECoV in adult healthy horses. The study focused on the detection
of IgG-specific antibodies against ECoV because the IgG isotype has
been shown to persist in the blood of cattle experimentally infected
with BCoV for up to 22 months, while the IgM isotype response to
BCoV only persisted up to 43 days (Tråvén et al., 2001). In our study,
the seroprevalence of ECoV was 9.6% in 5247 healthy, adult horses
from 18 different US states. Since follow-up data to determine the
duration of antibodies against ECoV in seropositive horses were un-
available, it is possible thatour cross-sectional studyunderrepresented
the true seroprevalence of ECoV in our sample set. Following exclu-
sion of the effect of farm origin, seropositivity was significantly
associatedwith horses from theMid-West, Draft horses and specific
uses including ranch/farmandbreedinguse. A Swedish studyof BCoV
in 2007 also found region was a significant variable, in addition to
herd size, biosecurity measures (i.e. boots for visitors) and distance
to the nearest herd (animal density; Ohlson et al., 2010). It would be
interesting to investigatewhether these risk factorsalsoapply tohorses,
but such information was unavailable for our study.
According to a study conducted in 1998 by the US Department
of Agriculture’s National Animal Health Monitoring System (USDA
NAHMS)1, the percentage of Draft horses was the highest in the
North-Eastern and Central regions. In our study population, 7% of
the horses from the Mid-West were Draft horses, compared to 2.6%,
3.7% and 6.3% from the West, South and North-East, respectively.
Furthermore, 60% of the study horses were used as ranch or farm
horses in the Mid-West and 33% of all Draft horses were used for
ranch and farmwork. Horses used for breeding in the Mid-West ac-
counted for 43% of the total Draft horses used for breeding across
regions. Therefore, factors contributing to the higher ECoV
seroprevalence in the Mid-West could be related to the higher
numbers of ECoV seropositive Draft horses used for farm/ranchwork
and breeding in that region.
Age was not a risk factor for seropositivity in the present study,
suggesting that infection rate among the various age groups was
probably similar. Previous studies have shown a wide range of age
susceptibility to clinical ECoV, including young Draft horses in Jap-
anese outbreaks and middle-aged horses in North American
outbreaks (Oue et al., 2011, 2013; Pusterla et al., 2013). One of our
study limitations was the lack of availability of blood samples from
horses <1 year old. Previous studies have shown that ECoV can fre-
quently be detected in the faeces of healthy foals and foals with
diarrhoea (Slovis et al., 2014). Further work is required to deter-
mine the seroprevalence of ECoV in horses <1 year old.
Apart from the possible correlation between Draft horses and
the Mid-West region, breed could also be correlated with specific
uses. Previous Japanese studies have reported ECoV outbreaks
1 See: Part I: Base line Reference of 1998 Equine Health and Management
www.aphis.usda.gov/animal_health/nahms/equine/downloads/equine98/
Equine98_dr_PartI.pdf (Accessed 3 January 2017).
Table 2
Equine coronavirus (ECoV) serologic status of 5247 healthy horses reported by geo-
graphic region, age, breed, sex and use.
ECoV
positive n (%)
ECoV
negative n (%)
Total
n (%)
Regiona (n)
North-East (650) 42 (6) 608 (94) 650 (12)
South (1907) 153 (8) 1754 (92) 1907 (36)
Mid-West (1302) 190 (15) 1112 (85) 1302 (25)
West (1388) 119 (9) 1269 (91) 1388 (26)
Age in years (n)
<1 (0) 0 0 0
1–5 (1006) 83 (8) 923 (92) 1006 (19)
6–10 (1490) 140 (9) 1350 (91) 1490 (28)
11–15 (1284) 121 (9) 1163 (91) 1284 (24)
16–20 (761) 77 (10) 684 (90) 761 (15)
>20 (599) 78 (13) 521 (87) 599 (11)
Not reported (107) 5 (5) 102 (95) 107 (2)
Breed (n)
Quarter horse (1567) 166 (11) 1401 (89) 1567 (30)
Warmblood (561) 46 (8) 515 (92) 561 (11)
Thoroughbred (844) 41 (5) 803 (95) 844 (16)
Paint (344) 37 (11) 307 (89) 344 (7)
Arabian (266) 33 (12) 233 (88) 266 (5)
Draft horse (238) 42 (18) 196 (82) 238 (5)
Pony/Miniature (269) 21 (8) 248 (92) 269 (5)
Other (1046) 115 (11) 931 (89) 1046 (20)
Not reported (112) 3 (3) 109 (97) 112 (5)
Sex (n)
Female (2196) 200 (9) 1996 (91) 2196 (42)
Maleb (2885) 294 (10) 2591 (90) 2885 (55)
Not reported (166) 10 (6) 156 (94) 166 (3)
Use (n)
Competition (2043) 156 (8) 1887 (92) 2043 (39)
Ranch/farm horse (2288) 274 (12) 2014 (88) 2288 (44)
Breeding (653) 63 (10) 590 (90) 653 (12)
Other (5) 1 (20) 4 (80) 5 (<1)
Not reported (258) 10 (4) 248 (96) 258 (5)
a Regions were defined as follows: North-East, NY, MD, PA; South, FL, MS, KY, TN,
NC, VA, TX; Mid-West, MO, OH, WI, MN; West, WA, CA, CO, WY.
b Male includes geldings and stallions.
Table 3
Results of the mixed effects logistic regression model for equine coronavirus (ECoV)
infection, including significant predictor variables and random effects parameters
expressed as odds ratios (OR) and 95% confidence intervals (95% CI) for risk factors
studied (region, age, breed, sex and use) in 5247 healthy US horses.
ECoV positivea ECoV negativeb P
OR 95% CI OR 95% CI
Regionc
North-East Ref Ref Ref Ref
South 1.04 0.68–21.62 0.95 0.62–1.47 0.831
Mid-West 1.84 1.17–2.87 0.54 0.35–0.85 0.008
West 1.25 0.80–1.95 0.80 0.51–1.25 0.323
Age in years
1–5 Ref Ref Ref Ref
5–10 1.12 0.82–1.53 0.89 0.65–1.21 0.472
11–15 1.13 0.82–1.58 0.88 0.64-1.22 0.437
16–20 1.18 0.82–1.70 0.85 0.59–1.21 0.375
>20 1.42 0.97–2.08 0.70 0.48–1.03 0.070
Breed
Quarter horse Ref Ref Ref Ref
Warmblood 0.98 0.65–1.46 1.02 0.68–1.52 0.924
Thoroughbred 0.48 0.32–0.74 2.07 1.36–3.15 0.001
Paint 0.99 0.65–1.50 1.01 0.67–1.53 0.957
Arabian 1.20 0.76–1.90 0.83 0.53–1.31 0.430
Draft horse 1.95 1.25–3.05 0.51 0.33-0.80 0.003
Pony/miniature 0.81 0.48–1.37 1.24 0.73–2.09 0.426
Other 1.04 0.78–1.40 0.96 0.71–1.30 0.790
Sexd
Female Ref Ref Ref Ref
Male — — — — —
Use
Competition Ref Ref Ref Ref
Ranch/farm horse 1.32 1.02–1.72 0.76 0.58–0.98 0.034
Breeding 1.59 1.09–2.31 0.63 0.43–0.92 0.016
Other 0.79 0.07–8.71 1.26 0.11–13.9 0.848
Ref, parameter used as reference category.
a Random effects parameter: OR = 2.39; 95% CI (2.00–2.99); Likelihood ratio test
vs. logistic regression: X2(1) = 40.42, P < 0.05.
b Random effects parameter: OR = 2.39; 95% CI (2.00–2.99); Likelihood ratio test
vs. logistic regression: X2(1) = 40.42, P < 0.05.
c North-East was considered reference for region; Quarter horse was considered
reference for breed; Competition was considered reference for use; Female was con-
sidered reference for sex; 1–5 year old horses were considered reference for age.
d Sex was not included in multivariate model due to non-significance in univari-
ate model.
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predominantly in racing Draft horses (Oue et al., 2013). It remains
to be determined if breed is directly linked to increased suscepti-
bility to ECoV infection or if the observations are confounded by
specific husbandry practices.
Seropositivity as it relates to use could possibly be related to farm
size. According to the NAHMS2, breeding farms are often relatively
large (>19 animals). More horses housed together and higher stock-
ing densities could increase the risk of ECoV transmission. This is
supported by a NAHMS study which reported that more horses/
farm increased the risk of illness. Because there are more foals and
young horses at breeding farms, such operations represent rela-
tively large, high-risk populations, which could contribute to
increased spread of ECoV and, hence, higher seroprevalence. Ad-
ditionally, up to 6% of the horses used for breeding in our study
population were Draft horses, which was higher than for other
breeds.
Climatic differences in the different geographical regions studied
could affect the environmental viability of the virus, thereby influ-
encing the risk of spread and seropositivity rates. The virus
responsible for severe acute respiratory syndrome (SARS) in humans,
also a β-coronavirus, is known to survive > 5 days outside the host
at a temperature of 22–25 °C and relative humidity of 40–50%. Higher
temperatures and/or humidity levels resulted in a rapid loss of vi-
ability (Chan et al., 2011). To the authors’ knowledge, there is no
information on the environmental viability of ECoV.
As with BCoV, clinical cases of ECoV in adult horses are diag-
nosed more frequently during the colder months of the year in the
USA (Pusterla et al., 2013). This observation probably relates to
husbandry-specific factors and the temperature-sensitivity of the
virus, which are likely to affect transmission rates of ECoV. Themajor
limitation of this study is the estimation of overall seroprevalence
of ECoV using a single data collection point, which could have un-
derestimated the general exposure rate. Robust longitudinal studies
are needed to further investigate the observations and risk factors
presented herein.
Conclusions
In this sample of 5247 healthy, adult horses from 18 states across
the USA, ECoV seroprevalence was 9.6%. Seropositivity was signifi-
cantly associated with region (Mid-West), breed (Draft horses) and
specific uses (ranch/farm and breeding). Longitudinal studies are
required to further investigate these findings.
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